The Vivalytic MRSA/SA test provides rapid diagnosis of methicillin resistance at the point of care

• As a rapid real-time PCR test at the point of care (POC), the Vivalytic MRSA/SA test can detect two of the most important pathogens associated with hospital-acquired infections.
• Differentiating whether the bacterial strain is methicillin resistant or methicillin sensitive promotes targeted therapy.
• The result is available in less than an hour, making the test a useful addition to crop determination, especially in emergency situations.
• Unnecessary and costly isolation measures that are stressful for patients can be avoided.

Waiblingen – The new Vivalytic MRSA/SA test for Bosch’s Vivalytic platform is now available. Bosch Healthcare Solutions has once again expanded the testing portfolio of this universal PCR system. The Bosch test, developed in collaboration with partner r-biopharm, detects methicillin-resistant staphylococcus aureus (MRSA), one of the most important pathogens for nosocomial infections and therefore for associated complications and mortality. In less than an hour, the Vivalytic MRSA/SA test delivers a reliable result directly at the point of care and is therefore particularly suitable for use in emergency rooms. Since the result of culture diagnostics is only available after one to three days, this point-of-care PCR test is ideal as an add-on tool when speed is of the essence. Rapid and reliable diagnosis of whether the bacterial strain is methicillin sensitive (MSSA) or resistant is also important in emergency situations. Waiting times for operations can, on the one hand, be shortened, while on the other hand, a decision on effective antibiotic treatment can be made on this basis. This capability helps prevent contamination, break the chain of infection and avoid further resistance, which in turn can have a positive impact on treatment procedure and costs. Last but not least, unnecessary isolation measures can be avoided, which are not only complex and expensive, but also put even more pressure on the patients.

MRSA risk
WHO estimates that the mortality rate of patients infected with MRSA is approximately 50% higher than patients who have been infected with non-resistant strains of Staphylococcus aureus. In addition, hospitalization time, morbidity, and medical costs increase significantly with MRSA infection. In Europe, approximately 149,000 clinical MRSA infections and approximately 7,000 deaths occur each year. Prevention and control measures, such as testing for MRSA, aim to reduce or avoid infections in hospital settings.

Vivalytic Platform: Simple application at the point of care
The advantages of rapid PCR tests administered with the help of Bosch’s Vivalytic platform lie not only in the fast analysis time, but also in the ease of use: once the sample is collected, the swab is inserted into the test cartridge. The cartridge, which contains all the reagents needed for the respective test, is then inserted into the Vivalytic analyzer for automated analysis. Handling and use are simple and medical professionals require only minimal training. Along with the new Vivalytic MRSA/SA test, the Vivalytic product portfolio also includes various tests for viral respiratory infections, such as SARS-CoV-2 – also as a pooling variant and as a lollipop test – as well as a multiplex test for sexually transmitted infections (IST).

Press contact:
Thomas Berroth
Marketing communication
Thomas.berroth2@de.bosch.com
+49 (0)711 811-45 599